EN DE

PCC Rokita SA (PCR) Fair Value & Analysis

Basic Materials · PL · Market cap 1.3B PLN

PR PCC Rokita SA PCR · WAR
Price66.00 PLN
Fair Value83.92 PLN
Upside+27.2%
Quality54/100
Watch PCC Rokita SA for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Thin margins · 3.1% net margin
Low debt · generates free cash flow
4.21% dividend yield
Mixed vs. peers (8/14)
Narrow moat 32/100
Evidence: High Range 62.94 PLN – 104.91 PLN Share as image

Fair value as of: Jul 12, 2026

From 24 valuation models · updated 29 days ago

Fair value updated Jul 12, 2026, revised from 51.59 PLN to 83.92 PLN (+62.7%) since Jun 24, 2026. Share price +3.1% over the past month.

A solid business, screening 27% undervalued on our models.

What matters now

  • Solid quality (54/100) at a price below fair value, the discount is the argument here, not the business quality.
  • Our model range runs from 62.94 PLN (bear) to 104.91 PLN (bull), base 83.92 PLN. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 54/100 (solid quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

103.62 PLN 40.40 PLN Fair Value 83.92 PLN Apr 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.

How to read this chart

60‑month range 40.40 PLN – 103.62 PLN · fair‑value band 62.94 PLN – 104.91 PLN · the 66.00 PLN price screens below the 83.92 PLN fair value. Dashed = 300-day average. As of Jul 12, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

PCC Rokita SA (PCR) currently trades at 66.00 PLN, while our model-based Fair Value estimate is 83.92 PLN, implying the stock looks roughly 27.2% undervalued today. The Quality Score stands at 54/100 (solid quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, PCC Rokita SA generated revenue of 1.8B PLN at a net margin of 3.4%. Revenue declined 12.0% year over year. It earns a return on equity of 4.5%. Net debt stands at 322M PLN. Fundamentals as of Jul 12, 2026

Our scenario range runs from 62.94 PLN (bear case) to 104.91 PLN (bull case); at 66.00 PLN, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 9% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -46% fair-value upside, at 27%, PCR screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 51.81 PLN 68.40 PLN 91.78 PLN 80
Residual Income 48.24 PLN 48.13 PLN 42.59 PLN 76
Rev-Margin DCF 38.98 PLN 58.80 PLN 82.22 PLN 74
All 24 models by family
DCF Models
FCF DCF 50.37 PLN 67.99 PLN 94.50 PLN 38
Owner Earnings 16.66 PLN 24.51 PLN 36.31 PLN 31
5Y Revenue Exit 38.98 PLN 57.56 PLN 82.55 PLN 39
5Y EBITDA Exit 61.96 PLN 97.08 PLN 140.17 PLN 41
5Y P/E Exit 34.70 PLN 50.20 PLN 67.27 PLN 38
10Y Revenue Exit 42.41 PLN 58.52 PLN 76.77 PLN 36
10Y EBITDA Exit 56.40 PLN 82.50 PLN 112.60 PLN 37
10Y P/E Exit 41.01 PLN 54.05 PLN 67.27 PLN 35
Earnings-Based
Graham-Dodd 20.64 PLN 38.46 PLN 47.73 PLN 54
EPV 21.57 PLN 25.93 PLN 29.56 PLN 59
Dividend Discount
Gordon GGM 39.38 PLN 50.45 PLN 60.64 PLN 70
DDM Multi-Stage 39.38 PLN 51.38 PLN 63.94 PLN 61
Multiples
P/E Multiple 38.69 PLN 51.59 PLN 64.49 PLN 63
P/S Multiple 38.69 PLN 51.59 PLN 64.49 PLN 58
P/B Multiple 38.69 PLN 51.59 PLN 64.49 PLN 55
EV/EBIT 40.54 PLN 57.52 PLN 74.50 PLN 53
EV/EBITDA 83.13 PLN 114.30 PLN 145.47 PLN 54
EV/Revenue 33.75 PLN 52.67 PLN 71.59 PLN 43
Asset-Based
NCAV (Graham) 33.46 PLN 44.84 PLN 66.92 PLN 50
Growth DCF
Growth DCF 51.81 PLN 68.40 PLN 91.78 PLN 80
Rev-Margin DCF 38.98 PLN 58.80 PLN 82.22 PLN 74
Economic Profit
Residual Income 48.24 PLN 48.13 PLN 42.59 PLN 76
ROIC Compounder 21.57 PLN 25.93 PLN 29.56 PLN 72
Growth Earnings
Growth-Adj P/E 27.83 PLN 39.75 PLN 51.68 PLN 68

Widest divergence: Growth DCF (58.80 PLN) versus Earnings-Based (25.93 PLN). Highest evidence: Growth DCF (80).

Notify me when PCR reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 1.8B PLN
Revenue growth (YoY) -12.0%
Net margin 3.4%
Return on equity 4.5%
Free cash flow 144M PLN FY2025
P/E ratio 25.3
More key figures
Operating margin 10.5%
EPS (TTM) 2.68 PLN
EPS growth (YoY) -80.4%
Net debt 322M PLN FY2025

Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 54/100

Of which business quality 54 · Market factors (momentum, volatility) 51

Profitability 32
Margins and returns on capital today
Quality Growth 18
Are margins and returns improving?
Cashflow 57
Earnings quality: real cash, not paper profit
Fin. Strength 58
Balance sheet, leverage, solvency risk
Investment 88
Disciplined investing over empire-building
Low Volatility 87
Calm price path (market factor)
Momentum 32
Price trend over the last 3–12 months (market factor)
52W Momentum 43
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

PCC Rokita SA designs, produces, and sells chemical products in Poland, Germany, the European Union, rest of Europe, the United States, Asia, and internationally. It operates through five segments: Polyurethanes, Chlorine Derivatives, Other Chemical Activities, Energy, and Other Activities.

Full company description

PCC Rokita SA designs, produces, and sells chemical products in Poland, Germany, the European Union, rest of Europe, the United States, Asia, and internationally. It operates through five segments: Polyurethanes, Chlorine Derivatives, Other Chemical Activities, Energy, and Other Activities. The Polyurethanes segment produces polyols, polyurethane systems, and prepolymers; and flexible foams, rigid foams, coatings, elastomers, adhesives, impregnations, and other products. The Chlorine Derivatives segment provides chlorine, sodium hydroxide, caustic soda, chlorobenzene, and hydrochloric acid. The Other Chemical Activities segment offers phosphorus-derivative and naphthalene-derivative products. The Energy segment produces and distributes electricity, thermal energy, demineralized water, and compressed air. The Other Operations segment is involved in the provision of maintenance services for technological equipment and installations; industrial waste management; hazardous goods transport services; management and administration services; environmental protection; asset management and security; construction and repairs of steel industrial equipment; and trades in chemical products, and other. It also provides transport and freight, and maintenance services; research of chemical substances; and designs, constructs, and assembles, as well as repairs industrial equipment, tanks, pipelines, and welded structure. The company sells its products under the Crossin, Ekoprodur, ROKOPOL, and ROKESTER brands. PCC Rokita SA was incorporated in 2002 and is headquartered in Brzeg Dolny, Poland. PCC Rokita SA is a subsidiary of PCC SE.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

PCC Rokita SA reported revenue of 1.8B PLN in FY2025 versus 2.2B PLN in FY2021, a compound −4.9%/yr. Reported net income was 61.5M PLN in FY2025, compounding −38.0%/yr from FY2021.

Growth Quality 61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
1.8B PLN
Latest YoY
−7.5%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−16.9%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.1%
Avg. growth/yr (13Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.2%
Revenue −4.9%/yr
FY21 2.2B PLN
FY22 3.1B PLN
FY23 2.4B PLN
FY24 1.9B PLN
FY25 1.8B PLN
Net income −38.0%/yr
FY21 417M PLN
FY22 675M PLN
FY23 268M PLN
FY24 143M PLN
FY25 61.5M PLN
Character of growth · EPS growth decomposed (2013-2024) +19.2 % p.a.
Revenue per share +9.2 pp

of which total revenue +9.7 pp · buybacks/dilution −0.5 pp

EBIT margin +8.8 pp
Tax rate −1.0 pp
Residual (interest, one-offs) +2.2 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch PCR: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "PCC Rokita SA Fair Value". https://www.fairvalue-calculator.com/stock/PCR

Peer Group

Chemicals · 333 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 54 · Above median
Fair Value upside +27% · Top 25%
Return on equity (TTM) 4% · Below median
Return on assets 3% · Above median
Net margin (TTM) 3% · Below median
Operating margin (TTM) 1% · Bottom 25%
Revenue growth -15% · Bottom 25%
Dividend yield (TTM) 4.2% · Top 25%
Debt / equity 0.24× · Higher than median

Valuation Multiples vs Chemicals median · lower = cheaper

P/E (TTM) 23.9× · Cheaper than median
P/B 0.26× · Cheaper than 75% of peers
P/S (TTM) 0.20× · Cheaper than 75% of peers
P/FCF 2.4× · Pricier than median
EV/EBITDA 2.3× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 70 · sector 0
FUTURE 0 · sector 20
PAST 15 · sector 19
HEALTH 88 · sector 94
DIVIDEND 84 · sector 27

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).

Stock Price Fair Value vs Fair Value
BASF SE BASN 1,034 MXN 532.13 MXN -49%
Ningxia Baofeng Energy Group 600989 ¥20.32 ¥20.17 -1%
Zhejiang Juhua Co 600160 ¥42.85 ¥23.35 -46%
PT Barito Pacific Tbk, BRPT 1,690 IDR 1,628 IDR -4%
LG Chem, Ltd 051910 260,500 KRW 587,755 KRW +126%
Formosa Chemicals & Fibre Corporation 1326 66.10 TWD 6.79 TWD -90%
PTT Global Chemical Public Company PTTGC 35.50 THB 18.21 THB -49%
542812 542812 ₹4,369 ₹791.05 -82%
Indorama Ventures Public Company IVL 24.50 THB 17.95 THB -27%
Navin Fluorine International Limited NAVINFLUOR ₹8,650 ₹2,146 -75%

Compare PCC Rokita SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is PCC Rokita SA (PCR) overvalued or undervalued?
As of Jul 12, 2026, our model estimates a fair value of 83.92 PLN versus a price of 66.00 PLN, about +27% (undervalued).
What is the fair value of PCR?
Our model-based fair value for PCC Rokita SA is 83.92 PLN (as of Jul 12, 2026), built from audited fundamentals. The current price is 66.00 PLN.
What is the quality score of PCR?
PCC Rokita SA has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of PCC Rokita SA (PCR)?
PCC Rokita SA reported trailing-twelve-month revenue of about 1.8B PLN (latest available figure, as of Jul 12, 2026).
What is the net profit margin of PCR?
The net profit margin of PCC Rokita SA is about 3.4%, meaning it keeps roughly 3.4% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track PCC Rokita SA and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.